FDA Approvals, Pathways and Case Studies

Achieving market authorization in the United States requires a precise understanding of evidence standards, meeting strategies, and documentation quality. FDA Approvals, Pathways & Case Studies equips teams with the practical insights needed to move from IND to marketing authorization with fewer surprises and stronger dossiers. This session unpacks how to select and defend a pathway—traditional, 505(b)(1) vs 505(b)(2), ANDA, or accelerated options such as Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review—while aligning CMC, nonclinical, clinical, and labeling narratives into a coherent risk–benefit story. Attendees will see how pre-IND, End-of-Phase, and Type C meetings can de-risk development, how to respond to information requests, and how to handle Complete Response Letters with data-driven remediation plans. For professionals actively searching for an Pharmaceutical Conference, the track provides current thinking from recent decisions, advisory committee discussions, and guidance updates that shape study design, statistical analyses, and post-marketing commitments.

Beyond pathway selection, the program focuses on submission craftsmanship: eCTD structure, Module 2 writing, cross-referencing, and traceability that lets reviewers verify claims efficiently. Case studies illustrate common pitfalls—insufficient control strategy in Module 3, inconsistent endpoint hierarchy, or unaddressed safety signals—and demonstrate corrective actions that lead to resubmission success. We also examine combination products and digital health tools, where human factors, software lifecycle documentation, and real-world performance evidence are increasingly important.

A special emphasis is placed on practical labeling development, REMS design, and risk communication strategies that survive both medical and legal scrutiny. Participants will leave with checklists for readiness reviews, playbooks for advisory committee prep, and templates that keep submissions inspection-ready. Foundational knowledge of NDA and BLA pathways is reinforced throughout, so cross-functional stakeholders—from CMC and clinical to medical affairs and HEOR—understand how their data will be judged in the U.S. regulatory context.